| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
- Myeloid-derived suppressor cells (MDSCs) accumulation and immunosuppressive activity-related targets [1]
|
|---|---|
| ln Vitro |
- Baccatin III inhibited the immunosuppressive activity of MDSCs in vitro. At concentrations of 5, 10, and 20 μM, it reversed MDSC-mediated suppression of T cell proliferation by 32±3%, 58±4%, and 75±5%, respectively [1]
- It did not affect the viability of MDSCs or T cells at concentrations up to 20 μM, with cell viability maintained above 90% [1] - It downregulated the expression of immunosuppressive molecules (arginase-1, iNOS) in MDSCs: 20 μM reduced arginase-1 activity by 62±4% and iNOS mRNA levels by 57±3% [1] |
| ln Vivo |
- In C57BL/6 mice bearing LLC Lewis lung carcinoma: Intraperitoneal injection of Baccatin III (5, 10 mg/kg, every other day for 14 days) dose-dependently reduced MDSC accumulation. The percentage of Gr-1⁺CD11b⁺ MDSCs in the spleen decreased by 35±3% (5 mg/kg) and 52±4% (10 mg/kg), and in tumor tissues by 42±3% (5 mg/kg) and 61±5% (10 mg/kg) [1]
- It enhanced antitumor immunity: 10 mg/kg Baccatin III increased CD4⁺ and CD8⁺ T cell proliferation in tumor-draining lymph nodes by 48±4% and 55±5%, respectively, and elevated IFN-γ production by T cells by 63±4% [1] - It inhibited tumor growth: 10 mg/kg dose reduced tumor volume by 58±4% and tumor weight by 62±3% compared to the control group [1] - Similar effects were observed in B16-F10 melanoma-bearing mice: 10 mg/kg Baccatin III reduced splenic MDSCs by 49±4% and tumor growth by 55±3% [1] |
| Cell Assay |
- MDSC isolation and culture assay: MDSCs were isolated from the spleen of LLC tumor-bearing mice by magnetic bead sorting (Gr-1⁺CD11b⁺ selection). Isolated MDSCs were incubated with Baccatin III (5, 10, 20 μM) for 24 hours, then co-cultured with CFSE-labeled splenic T cells (from naive mice) for 72 hours. T cell proliferation was analyzed by flow cytometry [1]
- Immunosuppressive molecule detection assay: MDSCs treated with Baccatin III (10, 20 μM) for 24 hours were lysed. Arginase-1 activity was measured by colorimetric assay; iNOS mRNA levels were detected by RT-PCR [1] - Cell viability assay: MDSCs and T cells were treated with Baccatin III (5–20 μM) for 24 hours, and viability was measured by MTT assay [1] |
| Animal Protocol |
- LLC Lewis lung carcinoma model: C57BL/6 mice (6–8 weeks old) were subcutaneously injected with LLC cells (5×10⁶ cells/mouse) into the right flank. When tumors reached 50–100 mm³, mice were randomly divided into control (vehicle) and Baccatin III groups (5, 10 mg/kg, intraperitoneal injection every other day for 14 days). Tumor volume was measured every 3 days; mice were sacrificed, and spleen/tumor tissues were collected for flow cytometry (MDSC percentage) and T cell function analysis [1]
- B16-F10 melanoma model: Mice were subcutaneously injected with B16-F10 cells (2×10⁶ cells/mouse). Baccatin III (10 mg/kg) was administered as above. Tumor growth and MDSC accumulation were evaluated similarly [1] - Baccatin III was dissolved in DMSO (final concentration ≤5%) and diluted with normal saline before injection [1] |
| Toxicity/Toxicokinetics |
No significant systemic toxicity was observed: Mice treated with baccatin III (at doses up to 10 mg/kg) did not show significant weight loss, and no abnormal damage was found in liver and kidney histology [1]
- At therapeutic concentrations, baccatin III did not produce cytotoxicity against normal immune cells (T cells, B cells) [1] |
| References | |
| Additional Infomation |
Baccatin III is a tetracyclic diterpenoid compound isolated from plants of the genus Taxus. It is a plant metabolite. It is a tetracyclic diterpenoid compound with structures of acetate and benzoate. It is derived from the hydride of taxane. Baccatin III has been reported to exist in Taxus sumatrana, Taxus cuspidata, and other organisms with relevant data. Baccatin III is a compound extracted from the needles of Taxus baccata and used as a precursor to paclitaxel.
- Baccatin III is a natural diterpenoid compound isolated from the genus Taxus and is a key precursor for the semi-synthesis of paclitaxel[1] - Its antitumor mechanism involves targeting myeloid-derived suppressor cells (MDSCs) to reduce their accumulation and immunosuppressive activity, thereby restoring antitumor T cell responses[1] - Unlike paclitaxel, it exerts its antitumor effect primarily through immunomodulation rather than direct cytotoxicity on tumor cells[1] |
| Molecular Formula |
C31H38O11
|
|---|---|
| Molecular Weight |
586.6268
|
| Exact Mass |
586.241
|
| CAS # |
27548-93-2
|
| PubChem CID |
65366
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
713.6±60.0 °C at 760 mmHg
|
| Melting Point |
229-234 °C
|
| Flash Point |
226.9±26.4 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.605
|
| LogP |
4.06
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
42
|
| Complexity |
1200
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)C)O)C)OC(=O)C
|
| InChi Key |
OVMSOCFBDVBLFW-VHLOTGQHSA-N
|
| InChi Code |
InChI=1S/C31H38O11/c1-15-19(34)13-31(38)26(41-27(37)18-10-8-7-9-11-18)24-29(6,20(35)12-21-30(24,14-39-21)42-17(3)33)25(36)23(40-16(2)32)22(15)28(31,4)5/h7-11,19-21,23-24,26,34-35,38H,12-14H2,1-6H3/t19-,20-,21+,23+,24-,26-,29+,30-,31+/m0/s1
|
| Chemical Name |
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-1,9,15-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~56.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7047 mL | 8.5233 mL | 17.0465 mL | |
| 5 mM | 0.3409 mL | 1.7047 mL | 3.4093 mL | |
| 10 mM | 0.1705 mL | 0.8523 mL | 1.7047 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
